

Do-Youn Oh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7977536/do-youn-oh-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

221
papers

7,697
citations

36
h-index

84
g-index

244
ext. papers

11,083
ext. citations

5.2
avg, IF

5.94
L-index

#	Paper	IF	Citations
221	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2461-2471	40	1123
220	Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 317-327	59.2	826
219	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2016 , 387, 968-977	40	694
218	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020 , 21, 671-684	21.7	402
217	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 276-282	2.2	357
216	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020 , 21, 796-807	21.7	264
215	Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. <i>Annals of Surgery</i> , 2018 , 268, 215-222	7.8	258
214	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. <i>European Journal of Cancer</i> , 2014 , 50, 2072-81	7.5	203
213	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1431-1438	13.4	190
212	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015 , 10, e0139749	3.7	142
211	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015 , 17, 33	8.3	110
210	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020 , 147, 2190-2198	7.5	107
209	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009 , 65, 80-4	5.9	105
208	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. <i>Cancer Letters</i> , 2008 , 272, 296-306	9.9	104
207	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3185-3194	2.2	92
206	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3502-3502	2.2	90
205	Biliary tract cancer. <i>Lancet, The</i> , 2021 , 397, 428-444	40	87

204	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4000-4000	2.2	78
203	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016 , 7, 76604-76612	3.3	77
202	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015 , 47, 607-15	5.2	76
201	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020 , 23, 510-519	7.6	72
200	ATM in DNA repair in cancer. <i>Pharmacology & Therapeutics</i> , 2019 , 203, 107391	13.9	68
199	Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. <i>Cancer</i> , 2012 , 118, 6162-70	6.4	64
198	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 303-13	4.8	52
197	Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 387-387	2.2	51
196	Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in patients with pretreated biliary tract cancer 2020 , 8,		49
195	Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2015 , 47, 343-61	5.2	49
194	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2520-9	12.9	47
193	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016 , 48, 171-9	5.2	46
192	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016 , 7, 58007-58021	3.3	46
191	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial 2019 , 7, 30		43
190	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2017 , 49, 851-868	5.2	41
189	Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4117-4117	2.2	41
188	Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 254-262	7.6	40
187	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017 , 8, 2329-2341	3.3	39

186	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 335-335	2.2	37
185	Clinical Implications of VEGF, TGF- β , and IL-1 β in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013 , 45, 325-33	5.2	34
184	Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1145-1154	6.1	33
183	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA1-LBA1	2.2	31
182	Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) \pm tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4520-4520	2.2	31
181	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. <i>JAMA Oncology</i> , 2021 , 7, 1669-1677	3.4	31
180	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 115, 164-71	8.7	30
179	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4009-4009	2.2	29
178	Safety and activity of the TGF β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer 2021 , 9,		29
177	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. <i>Cancer Letters</i> , 2018 , 430, 123-132	9.9	28
176	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhialuronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 638-638	2.2	28
175	Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. <i>European Radiology</i> , 2016 , 26, 2771-8	8	26
174	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 1095-1103	1.03	26
173	Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 167-167	2.2	26
172	A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 217-217	2.2	26
171	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020 , 23, 143-153	7.6	26
170	Public awareness of gastric cancer risk factors and disease screening in a high risk region: a population-based study. <i>Cancer Research and Treatment</i> , 2009 , 41, 59-66	5.2	25
169	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.. <i>Lancet Oncology</i> , The 2022 ,	21.7	25

168	Infigratinib in patients with advanced cholangiocarcinoma with gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020 , 16, 2375-2384	3.6	24
167	Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. <i>Diagnostic Molecular Pathology</i> , 2011 , 20, 94-100		24
166	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4124-4124	2.2	22
165	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 597-606	7.6	21
164	Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. <i>Oncotarget</i> , 2017 , 8, 93117-93130	3.3	20
163	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 378-378	2.2	20
162	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1197-1207	3.5	19
161	Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019 , 26, 416-425	2.8	19
160	A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. <i>Investigational New Drugs</i> , 2012 , 30, 1164-74	4.3	19
159	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 477-477	2.2	19
158	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016 , 48, 28-36	5.2	18
157	Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 149-166	5.2	18
156	Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020 , 71, 422-425	11.6	18
155	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2015 , 15, 721	4.8	17
154	A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteogristim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. <i>Supportive Care in Cancer</i> , 2016 , 24, 1709-17	3.9	15
153	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919871126	5.4	15
152	Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. <i>Scientific Reports</i> , 2019 , 9, 11131	4.9	15
151	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2014 , 48, 13-25	4.8	15

150	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. <i>Clinical Epigenetics</i> , 2015 , 7, 63	7.7	15
149	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 61-70	12.9	14
148	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial. <i>JAMA Network Open</i> , 2019 , 2, e198243	10.4	14
147	Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. <i>Journal of Korean Medical Science</i> , 2014 , 29, 1094-101	4.7	14
146	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. <i>Cancer Science</i> , 2020 , 111, 513-527	6.9	14
145	Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 470-470	2.2	14
144	Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 1167-1179	5.2	14
143	Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 899-904	8.9	13
142	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA1-LBA1	2.2	13
141	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016 , 11, e0151406	3.7	13
140	TGF- β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. <i>Cancer Research and Treatment</i> , 2015 , 47, 101-9	5.2	13
139	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021 , 24, 946-958	7.6	13
138	NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	13
137	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 164-174	7.6	12
136	MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. <i>Cancer Letters</i> , 2019 , 465, 12-23	9.9	12
135	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016 , 115, 1201-1205	8.7	12
134	Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4155-TPS4155	2.2	12
133	Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3603-3603	2.2	12

132	More Accurate Prediction of Metastatic Pancreatic Cancer Patients Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016 , 11, e0145692	3.7	12
131	Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. <i>British Journal of Cancer</i> , 2019 , 121, 332-339	8.7	11
130	Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012 , 8, 282-91	1.9	11
129	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4152-TPS4152	2.2	11
128	A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS600-TPS600	2.2	11
127	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016 , 48, 990-7	5.2	11
126	Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 164-164	2.2	11
125	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016 , 19, 421-430	7.6	10
124	Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. <i>Cancer Letters</i> , 2017 , 411, 162-170	9.9	10
123	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016 , 16, 515	4.8	10
122	Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. <i>Pancreas</i> , 2020 , 49, 393-407	2.6	9
121	Pertuzumab in gastrointestinal cancer. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 243-53	5.4	9
120	Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 331-331	2.2	9
119	Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 824-824	2.2	9
118	Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 687-96	5.2	9
117	Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 33-39	8.9	9
116	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients. <i>British Journal of Cancer</i> , 2019 , 121, 230-236	8.7	8
115	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, LBA4-LBA4	2.2	8

114	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1515-24	6.1	8
113	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021 , 27, 713-718	12.9	8
112	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 233-41	4.4	7
111	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 707-14	4.9	7
110	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2015 , 15, 690	4.8	7
109	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. <i>Oncologist</i> , 2015 , 20, 926-33	5.7	7
108	MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)-based combinations in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS467-TPS467	2.2	7
107	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016 , 48, 1045-55	5.2	7
106	Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 945-956	5.2	7
105	Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021 , 28, 1-25	2.8	7
104	Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	7
103	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018 , 18, 252	4.8	6
102	MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS530-TPS530	2.2	6
101	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015 , 5, 3376-88	4.4	6
100	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 1178-1187	5.2	6
99	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. <i>Anticancer Research</i> , 2014 , 34, 4275-80	2.3	6
98	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 453-460	4.4	5
97	Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. <i>OncoTargets and Therapy</i> , 2019 , 12, 1717-1728	4.4	5

96	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. <i>OncoTargets and Therapy</i> , 2017 , 10, 5013-5030	4.4	5
95	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3076-3076	2.2	5
94	Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4090-4090	2.2	5
93	Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 315-315	2.2	5
92	Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4597-4597	2.2	5
91	GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 932-940	7.6	5
90	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019 , 4, e000575	6	5
89	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.. <i>European Journal of Endocrinology</i> , 2022 ,	6.5	5
88	Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. <i>Psycho-Oncology</i> , 2017 , 26, 1810-1817	3.9	4
87	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS468-TPS468	2.2	4
86	Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3063-3063 ²⁻²	2.2	4
85	Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems. <i>Journal of Korean Medical Science</i> , 2020 , 35, e117	4.7	4
84	ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. <i>Cancer Letters</i> , 2021 , 516, 38-47	9.9	4
83	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2019 , 24, 1037-e636	5.7	3
82	Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 523-523	2.2	3
81	A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 294-294	2.2	3
80	TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4143-TPS4143	2.2	3
79	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS3145-TPS3145	2.2	3

78	WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. <i>Gastric Cancer</i> , 2021 , 24, 1003-1020	3.6	3
77	Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. <i>Biomolecules</i> , 2019 , 9,	5.9	3
76	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2021 , 1	7.6	3
75	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical</i>	2.2	2
74	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 98-98	2.2	2
73	Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 276-276	2.2	2
72	Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4034-4034	2.2	2
71	Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 886-900	5.2	2
70	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021 , 53, 1096-1103	5.2	2
69	The prognostic role of soluble transforming growth factor- β related with soluble programmed death-ligand 1 in biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4094-4094	2.2	2
68	A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. <i>Investigational New Drugs</i> , 2021 , 39, 1324-1334	4.3	2
67	Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. <i>Cancer Research and Treatment</i> , 2021 , 53, 291-300	5.2	2
66	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2565-2565	2.2	2
65	Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. <i>Gut and Liver</i> , 2021 , 15, 466-475	4.8	2
64	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3113-3113	2.2	2
63	The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. <i>Biomedicines</i> , 2021 , 9,	4.8	2
62	The prognostic role of soluble transforming growth factor- β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer. <i>Liver International</i> , 2021 , 41, 388-395	7.9	2
61	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 1468-1482	21.7	2

60	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy. <i>Scientific Reports</i> , 2021 , 11, 296	4.9	2
59	Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. <i>Cancer Research</i> , 2022 , 82, P2-13-07-P2-13-07	10.1	2
58	Treatment for unresectable gastric cancer. <i>Journal of the Korean Medical Association</i> , 2015 , 58, 209	0.5	1
57	Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS490-TPS490	2.2	1
56	Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4050-4050	2.2	1
55	Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 517-517	2.2	1
54	A phase 2, open-label, multicenter study of durvalumab (MEDI4736) + tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4150-TPS4150	2.2	1
53	Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4079-4079	2.2	1
52	The role of soluble TGF-beta and its dynamics for predicting the prognosis in unresectable pancreatic cancer patients treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 288-288	2.2	1
51	HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhialuronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic pancreatic cancer (PaC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS513-TPS513	2.2	1
50	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 648-648	2.2	1
49	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 750-750	2.2	1
48	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).. <i>Gastric Cancer</i> , 2022 , 1	7.6	1
47	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. <i>Cancer Research and Treatment</i> , 2017 , 49, 454-463	5.2	1
46	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 344-344	2.2	1
45	A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 319-319	2.2	1
44	An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3054-3054	2.2	1
43	A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2521-2521	2.2	1

42	Prospective evaluation of the clinical implications of the tumor metabolism and chemotherapy-related changes in advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 261-261	2.2	1
41	Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2021 , 53, 471-479	5.2	1
40	Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021 , 28, 7545-7554	3.1	1
39	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4056-4056	2.2	1
38	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211042812	5.4	1
37	Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients. <i>Cancer Research and Treatment</i> , 2021 , 53, 199-206	5.2	1
36	Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS256-TPS256	2.2	1
35	Varlitinib in combination with gemcitabine and cisplatin for treatment-naïve advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 439-439	2.2	0
34	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 712-712	2.2	0
33	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4540-4540	2.2	0
32	DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4166-TPS4166	2.2	0
31	Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4164-TPS4164	2.2	0
30	Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.. <i>European Journal of Cancer</i> , 2022 , 169, 188-197	7.5	0
29	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016 , 68, 750-5	2.8	
28	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS366-TPS366	2.2	
27	Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS621-TPS621	2.2	
26	Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS639-TPS639	2.2	
25	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 686-686	2.2	

24	Prognostic implication of soluble programmed death-ligand 1 (sPDL1) and its dynamic changes during FOLFIRINOX chemotherapy in unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 306-306	2.2
23	Halo 110-101: Early safety results of pegvorhialuronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 408-408	2.2
22	The prognostic role of soluble transforming growth factor-β (sTGFβ) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 257-257	2.2
21	Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in advanced pancreatic cancer patients: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 311-311	2.2
20	Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4059-4059	2.2
19	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16800-e16800	2.2
18	ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1038-1038	2.2
17	Adjuvant treatment patterns and clinical outcomes in patients with curative resected ampulla of Vater cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 415-415	2.2
16	Change of skeletal muscle index during the chemotherapy as a prognostic factor of survival in pancreatic cancer patients receiving palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 363-363	2.2
15	Weight loss at the first month of palliative chemotherapy to predict survival outcomes in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 83-83	2.2
14	Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15197-e15197	2.2
13	Measurement of soluble Programmed Death-Ligand 1 (soluble PD-L1) to predict survival in biliary tract cancer patients treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11094-11094	2.2
12	Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 370-370	2.2
11	TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4075-4075	2.2
10	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23268-e23268	2.2
9	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 416-416	2.2
8	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 460-460	2.2
7	Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 454-454	2.2

- 6 Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. *Journal of Clinical Oncology*, **2012**, 30, 3624-3624 2.2
- 5 Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. *Journal of Clinical Oncology*, **2012**, 30, e14617-e14617 2.2
- 4 Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.. *Journal of Clinical Oncology*, **2021**, 39, e14552-e14552 2.2
- 3 A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. *Investigational New Drugs*, **2021**, 39, 1624-1632 4.3
- 2 A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. *Clinical and Translational Science*, **2021**, 14, 990-1001 4.9
- 1 Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).. *Journal of Clinical Oncology*, **2021**, 39, TPS185-TPS185 2.2